Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing L-carnitine may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for
Levocarnitine Paediatric contains levocarnitine which is a type of protein. It is used to treat primary and secondary levocarnitine deficiency in children less than 12 years of age, infants and newborns. Levocarnitine deficiency occurs when the body has a shortage of levocarnitine. Levocarnitine Paediatric makes up for the body's lack of levocarnitine and helps give the body more energy. 2.
e your child Levocarnitine Paediatric
Do not give your child Levocarnitine Paediatric –
if your child is allergic to levocarnitine or any of the other ingredients of this medicine (listed in section 6).
Warnings and precautions Talk to your doctor before you give your child Levocarnitine Paediatric if your child: has severe kidney problems or kidney disease and is having dialysis. is diabetic and taking insulin, or any other drug to treat their diabetes. is taking anticoagulant medicine, such as warfarin, or any other drug to reduce blood clotting. has an intolerance to some sugars.
1
Other medicines and Levocarnitine Paediatric Tell your doctor if your child is taking anticoagulant medicine, such as warfarin, or any other drug to reduce blood clotting. Your doctor may need to change how often your child is tested to see how fast their blood clots. Tell your doctor or pharmacist if your child is taking, has recently taken or might take any other medicines. Pregnancy, breast-feeding and fertility As this medicine is used to treat children less than 12 years of age, infants and newborns, the information is not necessary for Levocarnitine Paediatric. Levocarnitine Paediatric contains sorbitol (E420), sodium methyl parahydroxybenzoate (E219) and sodium This medicine contains 52.5 mg sorbitol in each ml of solution. Sorbitol is a source of fructose. If your doctor has told you that your child has an intolerance to some sugars or if your child has been diagnosed with hereditary fructose intolerance (HFI), a rare genetic disorder in which a person cannot break down fructose, talk to your doctor before your child receives this medicine. Sorbitol does not cause dental caries and this product can be considered as sugar-free. This medicine contains approximately 1.5 mg sodium methyl parahydroxybenzoate in each ml of solution and may increase jaundice (yellowing of the skin and eyes) in newborn babies (up to 4 weeks old). It may cause allergic reactions (possibly delayed). This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodium-free'. 3.
your child Levocarnitine Paediatric
Always give your child this medicine exactly as your doctor has told you. Check with your doctor if you are not sure. How much Levocarnitine Paediatric should you give to your child Your doctor will carefully calculate the amount of Levocarnitine Paediatric that your child should take and may vary it depending on their response to the treatment. Your doctor may take blood and urine samples to check the amount of the drug in your child's body. Administration and instructions for use Levocarnitine Paediatric is for oral use. Carefully measure the dose your doctor has told you to take using the provided dosing syringe and bottle adaptor. 1. Open the bottle: Press downward on the cap and turn it counter-clockwise (Figure 1). 2. First time use only: A bottle adaptor is provided with the oral syringe. This is the device that gets inserted into the neck of the bottle to make it easier to withdraw the solution using the 2
oral syringe. With the bottle on a flat surface, insert the bottle adaptor into the bottle neck while keeping the bottle adaptor's flat surface facing up and pressing on it (Figure 2).
3. Push the syringe plunger to the bottom of the barrel of the syringe (toward its tip) to remove excess air. Attach the syringe to the bottle adaptor with a slight twisting motion (Figure 3). 4. Invert the bottle (with the syringe attached) and fill the syringe with the liquid by pulling the syringe plunger down to just beyond the graduation mark corresponding to the quantity in millilitres (ml) prescribed by your doctor (Figure 4). Remove air bubbles from the syringe by pushing the plunger up to the appropriate graduation mark. 5. Return the bottle to an upright position with the syringe still in the bottle adaptor / bottle (Figure 5). 6. Remove the syringe from the bottle / bottle adaptor (Figure 6).
7. Empty the contents of the syringe directly into mouth by pushing the syringe plunger to the bottom of the syringe barrel (Figure 7). Or empty the syringe contents in a clean cup for diluting with water or fruit juices. 8. Rinse the syringe by drawing water into the syringe and pushing the syringe plunger to the bottom of the syringe barrel, at least three times (Figure 8). 9. Replace the cap on the bottle (leaving the bottle adaptor in place in the bottle neck) (Figure 9).
3
Levocarnitine Paediatric solution can be drunk directly or diluted further with water or fruit juices. If diluted, it should be drunk within 40 minutes of preparation. Primary and secondary carnitine deficiency The usual dose of Levocarnitine Paediatric is up to 200 mg per kg of your child's bodyweight per day. This should be taken over 2-4 doses. Higher doses of up to 400 mg per kg of bodyweight per day may be necessary. Your doctor will tell you exactly how much medicine to give your child and when to give it. If you give your child more Levocarnitine Paediatric than you should If you give your child too much Levocarnitine Paediatric, contact your doctor or immediately go to the nearest hospital casualty department. If you forget to give your child Levocarnitine Paediatric Do not give your child a double dose to make up for a forgotten dose. Simply continue with the next dose as planned. If your child stops taking Levocarnitine Paediatric Do not stop giving your child this medicine without first talking to your doctor. If you have any further questions about giving your child this medicine, please ask your doctor or pharmacist. 4.
Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them. Very rare side effects (may affect up to 1 in 10,000 people) are: –
Mild stomach upsets such as stomach cramps or diarrhoea, or your child may feel or be sick for a short time. Drug-related body odour. Your doctor may reduce your child's dose to help lessen or stop the odour. For children also taking anticoagulant medicine, such as warfarin, tests may show their blood is taking longer than usual to clot.
Reporting of side effects If your child gets any side effects, talk to your doctor, pharmacist or nurse. This includes any
not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine. 5.
Levocarnitine Paediatric
4
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the bottle label and carton. The expiry date refers to the last day of that month. This medicinal product does not require any special storage conditions. 20 ml bottle: Discard after 30 days of first opening. 40 ml and 100 ml bottle: Discard after 60 days of first opening. As stated in section 3 "How to give your child Levocarnitine Paediatric", the paediatric solution can be drunk directly or diluted further with water or fruit juices. If diluted, it should be drunk within 40 minutes of preparation. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6.
What Levocarnitine Paediatric contains –
The active substance is levocarnitine. Each ml of oral solution contains 300 mg of levocarnitine (30 % w/v). The other ingredients are sorbitol (E420), sodium methyl parahydroxybenzoate (E219), sucralose (E955), cherry flavour, sodium hydroxide (E524), tartaric acid (E334) and purified water (see section 2, "Levocarnitine Paediatric contains sorbitol (E420), sodium methyl parahydroxybenzoate (E219) and sodium").
What Levocarnitine Paediatric looks like and contents of the pack Levocarnitine Paediatric is a clear, colourless to yellowish solution with cherry odour packaged in white plastic bottle containing either 20 ml, 40 ml or 100 ml of oral solution closed with a plastic child resistant, tamper evident cap. A 2 ml graduated oral syringe and a bottle adaptor are provided with the 20 ml pack size. A 5 ml graduated oral syringe and a bottle adaptor are provided with the 40 ml or 100 ml pack sizes. Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder Neon Healthcare Ltd. 8 The Chase, John Tate Road, Hertford, SG13 7NN, UK Manufacturer Conforma NV Zenderstraat 10, Destelbergen, B-9070, Belgium
5
This leaflet was last revised in 12/2024
6
Levocarnitine Paediatric 30 % oral solution Sugar Free/Alcohol Free comes as oral solution. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Levocarnitine Paediatric 30 % oral solution Sugar Free/Alcohol Free is l-carnitine.
Medicines with the same active substance, strength and form include: Levocarnitine Paediatric 30% Oral Solution alcohol free & sugar free. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Levocarnitine Paediatric 30 % oral solution Sugar Free/Alcohol Free, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Levocarnitine is indicated for the treatment of primary and secondary carnitine deficiency in children of under 12 years, infants and newborns.
Posology
Children under 12 years, infants and newborns
It is advisable to monitor therapy by measuring free and acyl carnitine levels in both plasma and urine.
The management of inborn errors of metabolism
The dosage required depends upon the specific inborn error of metabolism concerned and the severity of presentation at the time of treatment. However, the following can be considered as a general guide.
An oral dosage of up to 200mg/kg/day in divided doses (2 to 4) is recommended for chronic use in some disorders, with lower doses sufficing in other conditions. If clinical and biochemical symptoms do not improve, the dose may be increased on a short-term basis. Higher doses of up to 400mg/kg/day may be necessary in acute metabolic decompensation or the i.v. route may be required.
Haemodialysis - maintenance therapy
If significant clinical benefit has been gained by a first course of intravenous Levocarnitine then maintenance therapy can be considered using 1g per day of Levocarnitine orally. On the day of the dialysis oral Levocarnitine has to be administered at the end of the session.
Method of administration
For oral administration only. An oral syringe and a bottle adaptor are provided with a pack. The adaptor should be inserted in the bottle before use.
The paediatric solution can be drunk directly or diluted further with water or fruit juices. If diluted, it should be drunk within 40 minutes of preparation.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
While improving glucose utilisation, the administration of levocarnitine to diabetic patients receiving either insulin or hypoglycaemic oral treatment may result in hypoglycaemia.
Plasma glucose levels in these subjects must be monitored regularly in order to adjust the hypoglycaemic treatment immediately, if required.
The safety and efficacy of oral levocarnitine has not been evaluated in patients with renal insufficiency. Chronic administration of high doses of oral levocarnitine in patients with severely compromised renal function or in end stage renal disease (ESRD) patients on dialysis may result in an accumulation of the potentially toxic metabolites, trimethylamine (TMA) and trimethylamine-N-oxide (TMAO), since these metabolites are usually excreted in the urine. This situation has not been observed following intravenous administration of levocarnitine.
There have been very rare reports of International Normalised Ratio (INR) increased in patients treated concomitantly with levocarnitine and coumarinic drugs. See section 4.5 'Interactions' and section 4.8 'Undesirable Effects'.
Excipients
Sorbitol
The 30% oral solution contains sorbitol. Sorbitol is defined as non-cariogenic and this product can be considered as sugar-free.
The additive effect of concomitantly administered products containing sorbitol (or fructose) and dietary intake of sorbitol (or fructose) should be taken into account.
The content of sorbitol in medicinal products for oral use may affect the bioavailability of other medicinal products for oral use administered concomitantly.
Patients with hereditary fructose intolerance (HFI) should not take/be given this medicinal product.
Sodium methyl parahydroxybenzoate (E219)
This medicinal product contains approximately 1.5 mg sodium methyl parahydroxybenzoate per ml. Sodium methyl parahydroxybenzoate may increase jaundice (yellowing of the skin and eyes) in newborn babies (up to 4 weeks old). May cause allergic reactions (possibly delayed).
Sodium
This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodium-free'.
There have been very rare reports of International Normalised Ratio (INR) increased in patients treated concomitantly with levocarnitine and coumarinic drugs (see sections 4.4 and 4.8).
Pregnancy
Reproductive studies were performed in rats and rabbits. There was no evidence of a teratogenic effect in either species. In the rabbit but not in the rat there was a statistically insignificant greater number of post implantation losses at the highest dose tested (600mg/kg daily) as compared with control animals. The significance of these findings in man is unknown. There is no experience of use in pregnant patients with primary systemic carnitine deficiency.
Taking into account the serious consequences in a pregnant woman who has primary systemic carnitine deficiency stopping treatment, the risk to the mother of discontinuing treatment seems greater than the theoretical risk to the foetus if treatment is continued.
Breast-feeding
Levocarnitine is a normal component of human milk. Use of levocarnitine supplementation in nursing mothers has not been studied. Levocarnitine should only be used by nursing mothers if benefit to the mother outweighs any potential risks to the child from excess carnitine exposure.
Fertility
In three small clinical studies conducted on fertility, no safety issues were identified, however further studies are required to evaluate the effect of levocarnitine on fertility.
Levocarnitine Paediatric has no influence on the ability to drive and use machines.
Adverse reactions from any source are listed in the table below by MedDRA system organ class. Within each system organ class, the adverse drug reactions are ranked by frequency. Within each frequency grouping, adverse reactions are ranked in order of decreasing seriousness. In addition, the corresponding frequency category for each adverse drug reaction is based on the following conventions: very common (≥1/10); common (≥1/100, <1/10); uncommon (≥1/1,000, <1/100); rare (≥1/10,000, <1/1,000); very rare (<1/10,000).
SYSTEM ORGAN CLASS
FREQUENCY
ADVERSE REACTION
Gastrointestinal disorders
Very rare
Vomiting
Nausea
Diarrhoea
Abdominal cramp
General disorders and administration site conditions
Very rare
Body odour
Investigations
Very rare
International
Normalised Ratio increased *
* There have been very rare reports of International Normalised Ratio (INR) increased in patients treated concomitantly with levocarnitine and coumarinic drugs (acenocumarol and warfarin) –see section 4.4 'Special Warnings' and section 4.5 'Interactions'.
Decreasing the dosage often diminishes or eliminates drug related patient body odour or gastro-intestinal symptoms when present. Tolerance should be monitored very closely during the first week of administration and after any dosage increase.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
There have been no reports of toxicity from levocarnitine overdosage. Overdosage should be treated with supportive care.
Ask anything about Levocarnitine Paediatric 30 % oral solution Sugar Free/Alcohol Free. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.